Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 7/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19355131 | 0.93 | HPGDS (0.33) | PRKDCFAAHHPGDSCDK9RPS6KB1 | |
| SCHEMBL17634849 | 0.89 | PRKDC (0.44) | PRKDCFAAHCDK9CTSAGRM7 | |
| SCHEMBL17634786 | 0.86 | PRKDC (0.38) | PRKDCFAAHHPGDS | |
| SCHEMBL17874696 | 0.85 | PRKDC (0.48) | PRKDCFAAHCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17634839 | 0.85 | PRKDC (0.42) | PRKDCFAAHCDK9CTSAGRM7 | |
| SCHEMBL17634853 | 0.85 | PRKDC (0.42) | PRKDCFAAHCTSACYP1A2CYP3A4 | |
| SCHEMBL19355613 | 0.85 | PRKDC (0.42) | PRKDCFAAHCDK9CTSAGRM7 | |
| SCHEMBL19905144 | 0.85 | CYP1A2 (0.36) | HPGDSCDK9CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17634852 | 0.85 | PRKDC (0.44) | PRKDCFAAHCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL17634872 | 0.84 | PRKDC (0.42) | PRKDCFAAHCYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008305-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3459942-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2020-12-30 | — | — | EP | disclosed |
| US-10442791-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-10-15 | — | — | US | disclosed |
| US-10391095-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180193341-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-07-12 | — | — | US | disclosed |
| US-9925188-B2 | DNA-PK inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925188-B2 | DNA-PK inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-03-27 | — | — | US | disclosed |
| US-9878993-B2 | DNA-PK inhibitors for treatment of cancer | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878993-B2 | DNA-PK inhibitors for treatment of cancer | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-01-30 | — | — | US | disclosed |
| US-9592232-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-14 | — | — | US | disclosed |
| US-9592232-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-14 | — | — | US | disclosed |
| US-9376448-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376448-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-28 | — | — | US | disclosed |
| US-9296701-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296701-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008305-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PRKDC 33/4885FAAH 3955/4885HPGDS 918/4885 |
| US-10442791-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PRKDC 33/4885FAAH 3955/4885HPGDS 918/4885 |
| US-20180193341-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PRKDC 33/4885FAAH 3955/4885HPGDS 918/4885 |
| US-10391095-B2 | DNA-PK inhibitors | POLK, DTYMK, DCK | PRKDC 33/4885FAAH 3955/4885HPGDS 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.